Gene expression profiling of lung cancer cells following treatment with dasatinib

ABSTRACT: Mechanisms of resistance and sensitivity to the multi-targeted kinase inhibitor dasatinib are unknown. We previously found that lung cancer cells with kinase-inactivating BRAF mutations are sensitive to dasatinib and undergo senescence whereas cells with wild type BRAF are resistant. To better understand mechanisms underlaying the differential sensitivity of lung cancer cells to dasatinib, we performed gene expression profiling of lung cancer cells with (sensitive) and without (resistant) kinase-inactivating BRAF mutations

ORGANISM(S): Homo sapiens

PROVIDER: GSE69395 | GEO | 2016/11/01

SECONDARY ACCESSION(S): PRJNA285361

REPOSITORIES: GEO